Molnupiravir INN

Composition : Each Capsule Contains Molnupiravir INN 200mg.

Indication : It is indicated for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness.

Dosage and administration: Adults:The recommended dose of Molnupiravir is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days.The safety and efficacy of Molnupiravir when administered for periods longer than 5 days have not been established. Molnupiravir should be administered as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset.

Paediatric population: The safety and efficacy of Molnupiravir in patients below 18 years of age have not been established. No data are available.

Or, as directed by the registered physician.

Use in pregnancy and lactation : Pregnancy: There are no data from the use of Molnupiravir in pregnant women. Studies in animals have shown reproductive toxicity. Molnupiravir is not recommended during pregnancy. Women of childbearing potential should use effective contraception for the duration of treatment and for 4 days after the last dose of Molnupiravir.

Breast-feeding: It is unknown whether Molnupiravir or any of the components of molnupiravir are present in human milk, affect human milk production, or have effect on the breastfed infant. Animal lactation studies with molnupiravir have not been conducted.Based on the potential for adverse reactions on the infant from Molnupiravir, breast-feeding is not recommended during treatment and for 4 days after the last dose of Molnupiravir.

Packing: Each box contains 40’s capsules in container.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.